Semax

• Research themes include neurotrophin transcription, monoaminergic signalling, ischemia-related molecular responses and neurobiology models
• Most evidence is preclinical, and these themes are not clinical benefit claims.

CAS

80714-61-0

Formula

C₃₇H₅₁N₉O₁₀S

Molecular weight

About 813.9 Da

Appearance

White lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Store and ship according to the batch-specific COA, SDS and stability statement for the exact supplied form. Do not infer bulk-powder or solution stability from a foreign finished product; request matrix-specific solution-stability data when required.

MOQ

On request

Lead time

7–14 days

Semax is the synthetic linear heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), commonly described as an ACTH(4-7) fragment extended with Pro-Gly-Pro. It has a long Russian research history and substantial preclinical literature, but the available human studies are small, methodologically limited or focused on exploratory biomarkers and imaging. FDA's May 11, 2026 briefing review found insufficient evidence of effectiveness for the evaluated uses. Historical or foreign-market use does not establish FDA approval or suitability of this RUO lot for administration.

• Reported research topics include neurotrophin signalling, cognition-related models, ischemia and neural-injury models
• FDA's 2026 evaluation found insufficient evidence of effectiveness for cerebral ischemia, migraine or trigeminal neuralgia
• No FDA-approved or broadly validated therapeutic indication is established.

Animal and in-vitro studies report changes in BDNF/NGF-related transcription, dopaminergic and serotonergic readouts, and gene expression after experimental ischemia. Literature also discusses melanocortin-receptor interactions, but FDA's 2026 review found no clearly identified target receptor and notes that the contribution of metabolites remains unresolved. Exploratory biomarker or imaging changes do not establish direct nose-to-brain transport, a clinical mechanism or efficacy for an independently supplied RUO lot.

• This material is an RUO reagent, not a finished drug or sterile preparation
• FDA's 2026 review found no human pharmacokinetic study for either evaluated form and identified unresolved safety concerns, including potential aggregation- and impurity-related immunogenicity and a possible bleeding signal that could not be characterized from the available evidence
• Comprehensive long-term human safety is not established, and no human or veterinary administration guidance is provided.

Interactions reported in the literature

• No controlled interaction dataset supports combination recommendations for this RUO material
• Any co-exposure or formulation study requires its own compatibility, assay-interference and safety assessment.

Semax5 mg · WHJLP-SX5-260529-E

Semax10 mg · WHJLP-SX10-260529-E

Semax11 mg · WHJLP-SX11-260528-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• Request any additional sequence, content, aggregate, solvent or storage evidence only when the buyer's written procedure requires it and the scope has been agreed
• FDA specifically noted gaps in publicly available aggregate, bacterial-endotoxin and microbial-bioburden controls
• HPLC area purity alone does not establish identity, content, sterility, endotoxin status, immunogenicity risk or solution stability.

Store and ship according to the batch-specific COA, SDS and stability statement for the exact supplied form. Do not infer bulk-powder or solution stability from a foreign finished product; request matrix-specific solution-stability data when required.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• 1) FDA briefing evaluation dated May 11, 2026 (PCAC, Semax free base and Semax acetate): neither form is a component of an FDA-approved drug; FDA found insufficient evidence of effectiveness for cerebral ischemia, migraine or trigeminal neuralgia and concluded that the characterization, effectiveness and safety criteria weigh against 503A Bulks List inclusion. The scheduled advisory discussion is not a final determination. 2) Gusev et al. (2018, Zhurnal Nevrologii i Psikhiatrii, PMID 29798983): a 110-person post-ischemic-stroke rehabilitation study reported plasma BDNF and functional associations, but the abstract does not report randomization or blinding, so it does not establish broad clinical efficacy. 3) Lebedeva et al. (2018, Bull Exp Biol Med, PMID 30225715): a small resting-state fMRI study of 24 healthy volunteers (14 Semax, 10 placebo) reported a default-mode-network imaging difference after one exposure; this exploratory surrogate endpoint is not a clinical outcome. 4) Medvedeva et al. (2014, BMC Genomics 15:228, PMC3987924): a rat focal-cerebral-ischemia transcriptomic study reported 96 altered genes at 3 hours and 68 at 24 hours, supporting a preclinical research hypothesis rather than human efficacy.

1. 01

   Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain

   Journal of Neurochemistry · 2006 · peer-reviewed original research

   Open source
2. 02

   Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents

   Neurochemical Research · 2005 · peer-reviewed original research

   Open source
3. 03

   Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia

   Cellular and Molecular Neurobiology · 2010 · peer-reviewed original research

   Open source
4. 04

   Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats

   Genes (Basel) · 2020 · peer-reviewed original research

   Open source
5. 05

   Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome

   Medical Hypotheses · 2007 · hypothesis/opinion paper (peer-reviewed journal)

   Open source
6. 06

   The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease

   Acta Naturae · 2025 · peer-reviewed original research

   Open source
7. 07

   Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice

   British Journal of Pharmacology · 2025 · peer-reviewed original research

   Open source
8. 08

   FDA Evaluation of Semax-Related Bulk Drug Substances

   U.S. Food and Drug Administration · 2026 · regulatory scientific evaluation / government advisory committee briefing

   Open source